argenex (NASDAQ:ARGX – Free Report) had its target price reduced by Citigroup from $1,301.00 to $1,232.00 in a research report report published on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.
Other analysts also recently issued reports about the stock. Royal Bank Of Canada cut their price objective on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a report on Wednesday, October 21st. Citizens Jmp upped their target price on shares of argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of argenex in a research note on Wednesday, August 5th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of argenex in a report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,145.00.
Read Our Latest Stock Report on ARGX
argenex Trading Up 0.7%
Shares of NASDAQ:ARGX opened at $897.85 on Tuesday. The stock has a fifty day simple moving average of $946.51 and a two-hundred day simple moving average of $854.33. argenex has a 12-month low of $661.85 and a 12-month high of $1,072.75. The stock has a market capitalization of $56.46 billion, a price-to-earnings ratio of 31.33, a PEG ratio of 0.82 and a beta of 0.44.
argenex (NASDAQ:ARGX – Get Free Report) last released its earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. As a group, equities research analysts predict that argenex will post 28.63 EPS for the current year.
Institutional Trading of argenex
Large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of argenex in the third quarter worth about $8,139,000. Profund Advisors LLC grew its stake in shares of argenex by 11.9% during the 3rd quarter. Profund Advisors LLC now owns 619 shares of the company’s stock valued at $594,000 after acquiring an additional 66 shares during the period. ProShare Advisors LLC grew its stake in shares of argenex by 4.4% during the 3rd quarter. ProShare Advisors LLC now owns 946 shares of the company’s stock valued at $907,000 after acquiring an additional 40 shares during the period. Vise Technologies Inc. grew its stake in shares of argenex by 22.1% during the 3rd quarter. Vise Technologies Inc. now owns 1,018 shares of the company’s stock valued at $976,000 after acquiring an additional 184 shares during the period. Finally, Sage Rhino Capital LLC purchased a new stake in argenex in the 3rd quarter worth approximately $205,000. 60.32% of the stock is currently owned by institutional investors.
About argenex
argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.
argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.
See Also
- Five stocks we like better than argenex
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
